Trk receptor Inhibitors
The Tropomyosin receptor kinase (Trk) family consists of three transmembrane tyrosine kinases—TrkA, TrkB, and TrkC—which are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. These receptors are primarily expressed in the nervous system, where they serve as high-affinity receptors for neurotrophins: Nerve Growth Factor (NGF) binds to TrkA, Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-4 (NT-4) bind to TrkB, and Neurotrophin-3 (NT-3) binds to TrkC. Upon ligand binding, Trk receptors undergo dimerization and autophosphorylation of their intracellular tyrosine residues. This activates several key downstream signaling pathways, including the mitogen-activated protein kinase (MAPK/ERK) pathway, the phosphoinositide 3-kinase (PI3K/Akt) pathway, and the phospholipase C-gamma (PLC-gamma) pathway. These signals are essential for neuronal survival, axonal growth, and synaptic plasticity. While Trk signaling is vital for normal neurological development, oncogenic activation of these receptors is a potent driver of various human cancers. The most common mechanism of activation is the formation of NTRK gene fusions, where the 3' region of the NTRK gene is fused to the 5' region of a partner gene.
This results in the constitutive, ligand-independent activation of the Trk kinase domain. These fusions are found at high frequencies in rare cancers like secretory breast carcinoma and infantile fibrosarcoma, and at lower frequencies in more common tumors such as lung cancer, colorectal cancer, and glioblastoma. Beyond fusions, Trk overexpression or mutations have also been implicated in neuroblastoma and other malignancies. Furthermore, the TrkB/BDNF axis is known to promote epithelial-to-mesenchymal transition (EMT) and contribute to chemotherapy resistance and metastasis. The development of Trk inhibitors represents a milestone in tumor-agnostic precision medicine. Larotrectinib and entrectinib are the two primary first-generation Trk inhibitors approved by regulatory agencies. These are small-molecule, ATP-competitive inhibitors that show high potency and selectivity for the Trk kinase domain.
They are classified as Type I inhibitors. Entrectinib is notable for its additional activity against ROS1 and ALK kinases and its excellent central nervous system (CNS) penetration, which is crucial for treating brain metastases. These drugs have demonstrated remarkable and durable response rates in patients with NTRK fusion-positive tumors, regardless of the tissue of origin. Despite the initial success, the emergence of acquired resistance is a significant clinical challenge. Resistance often arises through solvent front mutations (e.g., G595R in TrkA or G623R in TrkC) or mutations in the gatekeeper residue, which physically block the binding of first-generation inhibitors. This has led to the development of second-generation Trk inhibitors, such as selitrectinib (LOXO-195) and repotrectinib, which are designed to overcome these specific mutations. Another challenge is the management of on-target side effects related to the physiological role of Trk in the nervous system, such as dizziness, ataxia, and weight gain.
Current research is focused on optimizing the sequencing of these therapies and exploring combination strategies to prevent or delay the onset of resistance. The success of Trk inhibitors serves as a paradigm for the development of targeted therapies based on molecular drivers rather than anatomical tumor location.
